Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
SKYSTAR BIO-PHARMACEUTICAL CO (SKBI)
|
Add to portfolio |
|
|
|
| Price: |
$0.00
| | Metrics |
| OS: |
8.7
|
M
| |
9
|
% ROE
|
| Market cap: |
|
| |
4
|
% ROIC
|
|
|
|
| |
|
|
|
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
|
|
| |
|
|
|
|
|
| |
|
|
| EPS |
$1.36
| |
0.0
|
x P/E
|
|
BVPS
|
$14.09
| |
0.00
|
x P/B
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 |
| Revenues | 42.4 | 33.6 | 54.4 | 46.9 | 33.8 | 25.6 | 15.1 | 9.8 |
| Revenue growth | 26.2% | -38.2% | 16.0% | 38.8% | 32.0% | 69.9% | 53.7% | |
| Cost of goods sold | 21.0 | 15.1 | 26.6 | 22.0 | 16.5 | 12.8 | 6.7 | 5.4 |
| Gross profit | 21.4 | 18.5 | 27.8 | 24.9 | 17.3 | 12.8 | 8.3 | 4.4 |
| Gross margin | 50.5% | 55.1% | 51.2% | 53.1% | 51.1% | 49.9% | 55.4% | 44.7% |
| Sales and marketing | 3.6 | 3.0 | 4.1 | 2.1 | 1.9 | 1.4 | 0.7 | 0.5 |
| Research and development | 1.0 | 2.2 | 2.8 | 0.7 | 1.2 | 0.5 | 0.3 | 0.1 |
| General and administrative | 4.0 | 4.7 | 4.1 | 4.6 | 2.5 | 2.7 | 2.4 | 0.9 |
| EBITA | 13.3 | 9.0 | 15.8 | 18.5 | 11.9 | 8.4 | 4.9 | 1.7 |
| EBITA margin | 31.3% | 26.6% | 29.0% | 39.5% | 35.3% | 32.7% | 32.7% | 17.6% |
| Amortization of intangibles | 0.2 | 0.4 | 0.5 | 0.4 | 0.2 | 0.2 | 0.0 | 0.0 |
| EBIT | 13.0 | 8.6 | 15.2 | 18.1 | 11.7 | 8.2 | 4.9 | 1.7 |
| EBIT margin | 30.7% | 25.4% | 28.0% | 38.6% | 34.6% | 32.0% | 32.5% | 17.2% |
| Pre-tax income | 12.9 | 8.4 | 16.5 | 17.4 | 10.9 | 7.1 | -0.9 | 1.7 |
| Income taxes | 2.4 | 2.2 | 2.9 | 3.3 | 2.0 | 1.5 | 1.0 | 0.5 |
| Tax rate | 18.6% | 25.9% | 17.4% | 19.0% | 18.7% | 21.5% | | 29.6% |
| Net income | 10.5 | 6.2 | 13.7 | 14.1 | 8.9 | 5.6 | -2.0 | 1.2 |
| Net margin | 24.8% | 18.5% | 25.1% | 30.1% | 26.2% | 21.9% | -13.0% | 12.0% |
| |
| Diluted EPS | $1.38 | $0.83 | $1.90 | $1.97 | $1.62 | $1.53 | ($0.15) | $0.09 |
| Shares outstanding (diluted) | 7.7 | 7.5 | 7.2 | 7.1 | 5.5 | 3.6 | 13.5 | 12.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|